Original article
Experts distinguish between around 200 different types of headaches, with migraines in particular being of great importance with millions of sufferers. Inadequate diagnostics, patients who have been taking over-the-counter medicines for years and a lack of information about adequate therapy make care difficult. But a lot has changed in terms of therapy options in the last few months, because the new CGRP antibodies are the first specific therapy for migraine prophylaxis available in Germany.
04.10.2019
Wohl zum ersten Mal in Deutschland stiftet ein Dienstleister einen Lehrstuhl. Dieser soll sich mit dem Themenkreis „Multimedikation und Versorgungsforschung“ beschäftigen und ist am Institut für Allgemeinmedizin der Johann Wolfgang Goethe-Universität in Frankfurt angesiedelt. „Monitor Versorgungsforschung“ sprach mit der Lehrstuhlinhaberin, Prof. Dr. Marjan van den Akker, dem Leiter des Instituts für Allgemeinmedizin der Johann Wolfgang Goethe-Universität in Frankfurt, Prof. Dr. Ferdinand Gerlach, und dem Stifter, Roland Lederer von INSIGHT Health.
04.10.2019
In August 2019, the Act for More Safety in the Supply of Medicines (GSAV) came into force. The aim of the law is to improve the quality and safety of drug supply. In addition to other topics relevant to the pharmaceutical market, this law also stipulates regulations that affect the biosimilar market in the GKV. On the one hand, the GSAV creates certain new regulations immediately, but also holds out the prospect of further changes after a period of three years. The latter concerns not least the interchangeability of biosimilars in pharmacies.
04.10.2019
The Martin Luther University of Halle-Wittenberg (MLU) was created in 1817 from the merger of the University of Wittenberg, founded in 1502, and the Friedrichs University of Halle, founded in 1694, and today offers a wide range of subjects in the humanities, social sciences, natural sciences and medicine sciences, which 340 professors teach to around 20,000 students. Since March 2011, one of these teachers has been Dr. Matthias Richter, university professor and at the same time director of the Institute for Medical Sociology (IMS), who in this role is responsible for the focus of his predecessor, Prof. Dr., who unfortunately died far too early. rer. soc. Wolfgang Slesina (born 1943, died 2013), continued.
04.10.2019
In mid-2018, Michael Müller, the Governing Mayor of Berlin, had a high-level meeting led by Prof. Dr. Karl Lauterbach (SPD) led a future commission entitled “Health City Berlin 2030”. The results report was presented in March of this year, containing many insights into Berlin's demographic development and the resulting challenges for health care; but also with recommendations that are sometimes difficult to implement. For example, the Future Commission recommends establishing an institutional collaboration between Charité - University Medicine Berlin and Vivantes - Network for Health. This could start with a common electronic patient file for all patients at Charité and Vivantes and extend to cooperation in research and transfer, the establishment of a task network and even coordinated strategy development. Former State Secretary Boris Velter, head of the “Health City Berlin 2030” office, which is jointly financed by Charité and Vivantes since August 2019, addressed the commission report in a keynote speech at the “Regional Forum Demography and Care Berlin – Brandenburg” and explained what needs to be done to gradually fill it with life.
04.10.2019
During the morning panel discussion, questions were posed by moderator Prof. Dr. Dr. Alfred Holzgreve the speakers of the first round: Thomas Müller, Head of Department 1 of the BMG, Dr. Antje Behring, acting head of the Medicines Department of the Federal Joint Committee (G-BA), and Prof. Dr. Jürgen diaperer, head of the Institute for Quality and Efficiency in Health Care (IQWiG).
04.10.2019
The first one sets the goal. The second describes the path there and the third names dangers and obstacles along the way. The goal setter at the 9th MVF specialist congress “Real World Evidence” in the Scharoun Hall of the AOK Nordost was Thomas Müller, head of Department 1 and therefore responsible within the BMG for pharmaceuticals, medical devices and biotechnology and the federal official who approved this from the German Bundestag the passed law for more safety in the supply of pharmaceuticals (GSAV), which, among other things, cleared the way for data collection during use. Dr. Dr. Antje Behring, acting head of the Medicines Department of the Federal Joint Committee (G-BA) and successor to Müller, who moved to the BMG around one and a half years ago. The third in the group and in the group was Prof. Dr. Jürgen diaperer, head of the Institute for Quality and Efficiency in Health Care (IQWiG) since September 2010. Of all people, he, who explained in the cover interview with “Monitor Healthcare Research” (1/18) two years ago that good registers can answer questions about patient adherence, doctors' prescribing behavior, check-ups and much more, is her However, they are not suitable for questions of benefit, the way forward must be worked out - on behalf of the G-BA.
04.10.2019
Following the innovation fund projects “Cardiolotse” (MVF 04/19) and Stroke OWL (MVF 05/19), the Mambo model project is presented in this issue, which aims to provide outpatient care and optimal care for people. This is intended to shed further light on the meta-topic of pilotage, which is probably one of the most obvious key elements of the innovation fund that needs to be transferred to standard care. However, unlike the innovative care solutions presented so far, the focus here is less on the case management approach, but rather on the coordination of all patient-relevant and sector-wide information, and, above all, investment in additional care time. To this end, the Mambo-MFAs employed by the doctors involved in the project work with the MONIKAs established by the project partner as a patient-centered, extended arm of the practices.
04.10.2019
Wenn in der Fortführung des Innovationsfonds die Ausschüttung der jährlichen Fördergelder von 300 auf 200 Millionen reduziert und für die Versorgungsforschung nur mehr 40 Millionen Euro (abzüglich 5 Millionen für Leitlinienentwicklung) übrig bleiben, weiß Prof. Dr. Holger Pfaff (IMVR), der scheidende Vorsitzende des Expertenbeirats des Innovationsfonds, genau, was kommen wird: „Der Konkurrenzdruck im Bereich Versorgungsforschung wird höher.“ Schon jetzt könne man voraussehen, dass künftig nicht mehr so viele Projekte bewilligt würden. Doch auch bei anderen Problemlagen ist der Innovationsfonds reparaturbedüftig, wie etwa bei den Detailthemen Evaluation und Transfer, wie Pfaff in der DKVF-Session „Projekte des Innovationsfonds“ zu Protokoll gab.
04.10.2019
Prof. Dr. At the beginning of the DKVF plenary session, Reinhard Busse (TU Berlin) led “Needs-based design of emergency care” with Prof. Dr. Ferdinand M. Gerlach, Chairman of the Expert Council for the Assessment of Developments in the Health Care System (SVR), an expert interview on the recommendations from the current SVR report on the topic of needs-based design of emergency care. Afterwards - moderated by Busse - the recommendations for integrated control centers (ILS) and integrated emergency centers (INZs) were discussed with Gerlach and representatives of the outpatient sector, the emergency services and the inpatient emergency room.